Status:
COMPLETED
Arimidex Observational: Reason for and Effect of Change From Tamoxifen
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
The purpose of this study is to analyse the effect on quality of life after 3 months of treatment after changing adjuvant therapy from tamoxifen to Arimidex.
Eligibility Criteria
Inclusion
- Postmenopausal
- Hormone sensitive breast cancer
- Patient uses tamoxifen or has stopped taking tamoxifen less than 7 days ago
Exclusion
- Visceral metastases
- Patients with signs of progression at the moment of changing therapy
- Patients who have used other endocrine treatments for breast cancer besides tamoxifen
Key Trial Info
Start Date :
July 1 2004
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00246961
Start Date
July 1 2004
Last Update
October 12 2007
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
's-Hertogenbosch, Netherlands
2
Research Site
Alkmaar, Netherlands
3
Research Site
Antwerpen, Netherlands
4
Research Site
Apeldoorn, Netherlands